Private Advisor Group LLC Grows Position in Gilead Sciences, Inc. $GILD

Private Advisor Group LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.7% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 50,035 shares of the biopharmaceutical company’s stock after purchasing an additional 4,010 shares during the quarter. Private Advisor Group LLC’s holdings in Gilead Sciences were worth $6,973,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in GILD. Optas LLC increased its stake in shares of Gilead Sciences by 9.3% in the 1st quarter. Optas LLC now owns 4,126 shares of the biopharmaceutical company’s stock worth $575,000 after acquiring an additional 351 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Gilead Sciences during the first quarter worth about $14,535,000. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its holdings in Gilead Sciences by 58.1% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 466,363 shares of the biopharmaceutical company’s stock worth $64,997,000 after purchasing an additional 171,300 shares during the period. Elevation Point Wealth Partners LLC grew its holdings in Gilead Sciences by 368.1% in the first quarter. Elevation Point Wealth Partners LLC now owns 25,126 shares of the biopharmaceutical company’s stock worth $3,502,000 after purchasing an additional 19,758 shares during the period. Finally, Platform Technology Partners increased its stake in shares of Gilead Sciences by 22.0% during the first quarter. Platform Technology Partners now owns 3,279 shares of the biopharmaceutical company’s stock valued at $457,000 after purchasing an additional 592 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the transaction, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. This represents a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 83,000 shares of company stock valued at $10,824,500 over the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 3.9%

Shares of NASDAQ:GILD traded up $5.05 during trading on Tuesday, reaching $134.66. 1,629,010 shares of the stock traded hands, compared to its average volume of 7,190,654. The stock has a market cap of $167.19 billion, a P/E ratio of 18.34 and a beta of 0.32. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The stock has a 50-day moving average of $129.44 and a two-hundred day moving average of $134.64. Gilead Sciences, Inc. has a 52-week low of $107.75 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were paid a $0.82 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. Gilead Sciences’s payout ratio is currently 44.69%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $133.00 to $155.00 in a research report on Monday. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a research note on Monday. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. The Goldman Sachs Group boosted their target price on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, April 17th. Finally, Jefferies Financial Group began coverage on Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price on the stock. Twenty-six analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $159.19.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.